Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression
Open Access
- 13 January 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 16 (1), 1-9
- https://doi.org/10.1186/s12885-016-2056-0
Abstract
FoxC2 is an epithelial–mesenchymal transition (EMT) regulator which induces metastasis. The purpose of this study is to assess the prognostic value of FoxC2 expression in non-small cell lung cancer (NSCLC), alone or in combination with E-cadherin expression. A retrospective study was conducted using immunohistochemistry to investigate FoxC2 and E-cadherin expression in a cohort of 309 patients with surgically resected NSCLCs. The prognostic value of FoxC2 and E-cadherin on overall survival (OS) and recurrence-free survival (RFS) was determined by Kaplan-Meier analysis and Cox proportional hazard models. High FoxC2 expression was detected in 26.5 % of tumors, and significantly correlated with tobacco use (p = 0.047), adenocarcinoma (p = 0.008) and nodal involvement (p < 0.001). Univariate analysis revealed its association with OS (p = 0.036) and RFS (p = 0.011). By multivariate analysis, high FoxC2 expression lost its significance as an independent predictor of recurrence (p = 0.077), while TNM stage, nodal status and the presence of high FoxC2 and impaired E-cadherin expression retained independent prognostic significance in relation to both OS and RFS. Subset analyses indicated that high FoxC2 expression was significantly associated with disease outcome in node-positive, but not in node-negative patients. Evaluation of FoxC2 expression, alone or in combination with E-cadherin expression, may help to stratify NSCLC patients for risk of disease progression, pointing to this EMT regulator as a potential prognostic marker.Keywords
Funding Information
- National Natural Science Foundation of China (81201834)
This publication has 23 references indexed in Scilit:
- The Foxc2 transcription factor regulates tumor angiogenesisBiochemical and Biophysical Research Communications, 2010
- Role of the epithelial-mesenchymal transition regulator Slug in primary human cancersFrontiers in Bioscience-Landmark, 2009
- Foxc2 Transcription Factor: A Newly Described Regulator of AngiogenesisTrends in Cardiovascular Medicine, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Distinct mechanisms of tumor invasion and metastasisTrends in Molecular Medicine, 2007
- Mesenchyme Forkhead 1 ( FOXC2 ) plays a key role in metastasis and is associated with aggressive basal-like breast cancersProceedings of the National Academy of Sciences of the United States of America, 2007
- Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nature Reviews Cancer, 2007
- Epithelial–mesenchymal transitions in tumour progressionNature Reviews Cancer, 2002
- Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas.2002
- Epithelial Mesenchymal Interactions in Cancer and DevelopmentCell, 2001